October 3, 2008
EDAP Features Ablatherm-HIFU and Sonolith I-Sys Devices At Two Prestigious Urological Congresses
LYON, France, Oct. 3, 2008 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its Ablatherm-HIFU and next generation Sonolith I-Sys devices were highlighted at two major European urological conferences: the 60th Annual Congress of the German Society of Urology (DGU) from September 24-27 and the Italian Society of Urology (SIU) from September 22-28.
Both congresses showcased EDAP's focus on increasing physician adoption of Ablatherm-HIFU technology and further clarifying the unique capabilities of its therapeutic ultrasound solution for localized prostate cancer. During workshops on the Ablatherm-HIFU device, urologists ranging from beginner to expert users of the technology had the opportunity to assess the device and its robotized approach while discussing peer-to-peer experiences with HIFU's clinical superiority as a safe and proven treatment option. Live Ablatherm-HIFU treatments were displayed to large audiences with direct commentary from expert physicians.During the DGU event in Germany, EDAP hosted a press meeting and symposium where four current Ablatherm-HIFU experts presented clinical results and shared their experiences utilizing HIFU non-invasive applications. Professor Rischmann, President of the French Association of Urology highlighted the Association's conclusion that HIFU is now considered a standard of care for salvage and primary care treatments for localized prostate cancer.
During the press meeting, Professor D. F. Wieland, from Regensburg University in Germany, commented, "With over 10 years of experience using Ablatherm-HIFU and our positive results obtained during these years, we fully support and welcome the French Association of Urology's designation of HIFU as a standard of care and expect the conclusion to extend throughout Europe."
Marc Oczachowski, EDAP's Chief Executive Officer, said, "I am very pleased with the success of both congresses held in key European countries where Ablatherm-HIFU continues to expand. EDAP's success at these two congresses confirmed the validity of our marketing program and provided us with an excellent forum to increase the adoption of our Ablatherm-HIFU device through our presentation of promising clinical results, peer-to-peer interactions, and live demonstrations of Ablatherm-HIFU."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com or http://www.urotoday.com/HIFU.
In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.
This news release was distributed by GlobeNewswire, www.globenewswire.com
CONTACT: EDAP TMS SA Investor Relations / Legal Affairs Blandine Confort +33 4 72 15 31 72 [email protected] The Ruth Group Investors: R.J. Pellegrino 646-536-7009 [email protected]